Altasciences acquires Calvert Laboratories

By The Science Advisory Board staff writers

May 6, 2021 -- Altasciences announced it has acquired Calvert Laboratories, a contract research organization (CRO) with operations in Pennsylvania and North Carolina.

The acquisition increases Altasciences' small molecule expertise, as well as adds pharmacology, ophthalmology, and carcinogenicity efficacy study capabilities to its current preclinical offering, the company reported in a statement.

Altasciences is a CRO that supports steps in early-stage drug development. Michael Recny, PhD, is the outgoing CEO of Calvert Laboratories.

Report finds CROs modernizing, accelerating clinical trials
Contract research organizations (CROs) are modernizing and speeding up clinical trials with 90% unifying their clinical operations, according to a new...
Science 37 launches CRO program for decentralized clinical trials
Science 37 has launched a partnership program called Science 37 Certified, which is designed to empower contract research organizations (CROs) with access,...
How is the pharma-AI partnership landscape changing?
Artificial intelligence (AI) is taking on a growing role in drug discovery and development, with some 250 firms in a market space that's worth over $9 billion....
Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider.
Florida CRO expands drug screening and manufacturing
Florida-based contract research organization (CRO) Alchem Laboratories is constructing a new building to grow its screening and chemical trail manufacturing...

Copyright © 2021

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter